Sonia Wolf: GLP-1 Receptor Agonists in Sickle Cell Disease
Sonia Wolf, Consultant Hematologist at Barts Health NHS Trust, shared American Society of Hematology‘s post on LinkedIn, adding:
“Really proud to have this letter published by American Society of Hematology and hope it leads to further work to make these drugs available to sickle cell patients who may benefit.”
American Society of Hematology shared a post on LinkedIn about a recent article by Sonia Wolf, published in The Hematologist, adding:
“Promising new studies highlight the potential of GLP-1 receptor agonists to reduce hospitalizations, ICU admissions, and all-cause mortality among individuals with sickle cell disease (SCD), as well as cardiovascular and vaso-occlusive events in those with both SCD and type 2 diabetes mellitus.”
Title: Are GLP-1 Receptor Agonists the Next Big Thing for Sickle Cell Disease?
Author: Sonia Wolf
Stay updated with Hemostasis Today.
-
Nov 1, 2026, 12:11Marine Sargsyan: Coronary Care Disparities Across the ESC EuroAsia Region
-
Nov 1, 2026, 12:00Ericka Robinson: Family Leave and the Importance of Workplace Support
-
Nov 1, 2026, 11:47Pranjal Patil: Anemia – Are We Treating the Cause or Just the Symptoms?
-
Nov 1, 2026, 11:29Sammee VanArsdale: Human FcRn Models – Advancing Long-Acting Biologics
-
Nov 1, 2026, 05:12Lorena Costa: Anemia Is Common, but It Is Not Normal
-
Nov 1, 2026, 04:57Artificial Intelligence in Blood Donor Management – ISBT
-
Nov 1, 2026, 04:50Neda Ashayeri: Fostering Knowledge Exchange at the Benign Hematology League Summit
-
Nov 1, 2026, 04:39Young Patient Voices Shaping the Future of Healthcare – EHC
-
Nov 1, 2026, 04:25Mary Cushman: Understanding Stroke in Patients with Cancer